Objective: To determine the incidence of symptomatic and incidental venous thromboembolism (VTE) at time of diagnosis and throughout the first year, in patients with suspected epithelial ovarian cancer (EOC).
Methods: Patients were recruited consecutively in the gynecological outpatient clinic at Aalborg University Hospital, Denmark from December 2014 to May 2017. All patients underwent a whole leg compression ultrasound scan (CUS), Computed Tomography (CT) of the thorax in arterial phase at time of inclusion, to be able to diagnose deep vein thrombosis (DVT) and pulmonary embolism (PE), respectively. Patients were followed and systematically screened for VTE throughout 12 months.
Results: Ninety-seven patients with suspected EOC were enrolled in the study and followed up. Within the group of EOC patients (N = 53) eleven were diagnosed with VTE during the first year from EOC diagnosis, the incidence of VTE at time of diagnosis was low (2/53-3.8%). No patients with borderline or benign ovarian neoplasms were diagnosed with VTE. One EOC patient had a VTE during the postoperative period and further eight EOC patients were diagnosed with VTE within the first year, during periods undergoing non-surgical cancer treatment. Median time to VTE was 87 days.
Conclusions: The one year cumulative incidence of VTE in EOC patients was 20.8% with a low incidence at time of diagnosis. A substantial number of VTE cases (73%) appeared during periods of non-surgical oncologic treatment. Future research should focus on risk factors and timing of VTE in EOC patients, as this could have important implications for future prophylaxis guidelines.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.thromres.2019.07.027 | DOI Listing |
Eur J Case Rep Intern Med
December 2024
Department of Internal Medicine, Ospedale Regionale di Lugano EOC, Lugano, Switzerland.
Unlabelled: This article describes a case of a 26-year-old female with a history of Evan's syndrome who presented with severe exertional dyspnoea and abdominal discomfort. The patient was diagnosed with chronic Budd-Chiari syndrome, a rare vascular disorder characterized by obstruction of the hepatic vein. We discuss the risk factors, the clinical manifestations, and diagnostic methods for Budd-Chiari syndrome, as well as the possible association with an underlying incomplete systemic lupus erythematosus.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Neurocenter of Southern Switzerland, Lugano, Ticino, Switzerland.
Background: Alzheimer's disease (AD) is the most common irreversible neurodegenerative disorder of the elderly. Its clinical diagnosis can be confirmed with expensive and invasive laboratory exams. Thus, new biomarkers and diagnostic tools to facilitate the proper management of patients are required.
View Article and Find Full Text PDFProstate Cancer Prostatic Dis
January 2025
South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia.
Background: Patients treated with RT and long-term androgen deprivation therapy (ltADT) for high-risk localized prostate cancer (HRLPC) with 1 high-risk factor (any of Gleason ≥8, PSA > 20 ng/mL, ≥cT3; "high-risk") have better outcomes than those with 2-3 factors and/or cN1 disease ("very high risk"). We evaluated whether this risk stratification could determine benefit from ltADT versus short-term (stADT).
Methods: The Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) repository of randomized trials was queried to identify eligible patients and trials.
Introduction: Niraparib was approved for first-line (1L) maintenance (1LM) treatment of patients with advanced epithelial ovarian cancer (EOC) following the PRIMA/ENGOT-OV26/GOG-3012 (PRIMA) trial. PRIMA was restricted to patients at higher risk of progression (excluded stage III EOC with no visible residual disease [NVRD] after primary cytoreductive surgery [PCS]). This retrospective study evaluated the potential impact of excluding stage III EOC with NVRD from PRIMA by assessing real-world treatment outcomes following 1LM niraparib monotherapy in this patient population.
View Article and Find Full Text PDFJ Ovarian Res
January 2025
College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Background: The benefit of cytoreduction with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for epithelial ovarian cancer (EOC) remains uncertain. This study investigated the relationship between serum cytokines, particularly monocyte chemoattractant protein-1 (MCP-1), a key inflammatory mediator, and recurrence risk in EOC patients undergoing CRS/HIPEC.
Methods: From January 2018 to January 2023, serum cytokine levels were analyzed in 34 EOC patients (17 primary, 17 recurrent) before and after CRS/HIPEC using MILLIPLEX Magnetic Bead Panels.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!